| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8724722 | Clinical Gastroenterology and Hepatology | 2018 | 69 Pages |
Abstract
In decision analysis of a hypothetical cohort of patients who met Rome IV criteria for IBS-D, we identified cost and accuracy thresholds that can guide investigators and payers as they develop, validate, price, and/or reimburse IBS-D biomarker tests for use in everyday clinical practice.
Keywords
PMPMFODMAPMCOIBS-DWTPIBDIBSCMSFGIDQALYFunctional gastrointestinal disorderInflammatory bowel diseaseBudget impactDiagnosticWillingness-to-payManaged care organizationquality-adjusted life yeardiarrhea-predominant irritable bowel syndromeirritable bowel syndromeModelingCenters for Medicare & Medicaid ServicesC-reactive proteinCRP
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Christopher V. Almario, Benjamin D. Noah, Alma Jusufagic, Daniel Lew, Brennan M.R. Spiegel,